Ixekizumab exposure associated with myelitis: A case report and a literature review

被引:3
作者
Romozzi, Marina [1 ,2 ]
Bellavia, Simone [1 ,2 ]
Caldarola, Giacomo [1 ,3 ]
De Simone, Clara [1 ,3 ]
Luigetti, Marco [1 ,2 ]
Calabresi, Paolo [1 ,2 ]
Di Filippo, Massimiliano [4 ]
Masullo, Carlo [1 ,2 ]
Lucchini, Matteo [1 ,2 ]
机构
[1] Fdn Policlin Univ Agostino Gemelli IRCCS, Largo A Gemelli 8, I-00168 Rome, Italy
[2] Univ Cattolica Sacro Cuore, Dipartimento Neurosci, Rome, Italy
[3] Univ Cattolica Sacro Cuore, Dipartimento Dermatol, Rome, Italy
[4] Univ Perugia, Clin Neurol, Dipartimento Med & Chirurgia, Osped Santa Maria Misericordia, Perugia, Italy
关键词
Ixekizumab; IL-17; Psoriatic arthritis; Myelitis; CNS inflammation; NEUROLOGICAL ADVERSE EVENTS; ACUTE TRANSVERSE MYELITIS; FACTOR-ALPHA THERAPY; DEMYELINATING DISEASE; ETANERCEPT; PSORIASIS; ANTIBODY; PATIENT; LESIONS; SAFETY;
D O I
10.1016/j.jneuroim.2021.577726
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We describe a case of a 28-year-old man who developed a cervical myelitis while exposed to ixekizumab (IL-17 inhibitor) for psoriatic arthritis. Spinal MRI showed a T2 hyperintense lesion at the C4-C5 level while brain MRI was unspecific. Oligoclonal bands were absent and extensive screening for autoimmunity was negative. Rechallenge with ixekizumab was positive corroborating a relation between drug exposure and the neurological event. To the best of our knowledge, this is the first case of CNS inflammatory adverse event associated with ixekizumab. We also provide a review of case reports of demyelinating disorders associated with the use of biologic drugs for the treatment of psoriasis and psoriatic arthritis.
引用
收藏
页数:6
相关论文
共 44 条
  • [21] OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results
    Kimball, Alexa B.
    Rothman, Kenneth J.
    Kricorian, Gregory
    Pariser, David
    Yamauchi, Paul S.
    Menter, Alan
    Teller, Craig F.
    Aras, Girish
    Accortt, Neil A.
    Hooper, Michele
    Rice, Kara Creamer
    Gelfand, Joel M.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (01) : 115 - 122
  • [22] Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden
    Kopp, Tine Iskov
    Delcoigne, Benedicte
    Arkema, Elizabeth V.
    Jacobsen, Rikke Kart
    Magyari, Melinda
    Ibfelt, Else Helene
    Locht, Henning
    Sellebjerg, Finn
    Cordtz, Rene Lindholm
    Jensen, Dorte V.
    Askling, Johan
    Dreyer, Lene
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (05) : 566 - 572
  • [23] Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events
    Kunchok, Amy
    Aksamit, Allen J., Jr.
    Davis, John M., III
    Kantarci, Orhun H.
    Keegan, B. Mark
    Pittock, Sean J.
    Weinshenker, Brian G.
    McKeon, Andrew
    [J]. JAMA NEUROLOGY, 2020, 77 (08) : 937 - 946
  • [24] Leonardi CL, 2008, LANCET, V371, P1665, DOI 10.1016/S0140-6736(08)60725-4
  • [25] Defining the disease course of TNFα blockers-associated Multiple Sclerosis
    Lucchini, Matteo
    Giuffre, Guido Maria
    Nociti, Viviana
    Bianco, Assunta
    De Fino, Chiara
    Losavio, Francesco Antonio
    Presicce, Giorgia
    Calabresi, Paolo
    Mirabella, Massimiliano
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2021, 353
  • [26] Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature
    Mahil, Satveer K.
    Andrews, Thomasin C.
    Brierley, Charlotte
    Barker, Jonathan N.
    Smith, Catherine H.
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2013, 24 (01) : 38 - 49
  • [27] Extensive and severe CNS demyelination associated with golimumab therapy
    Maillart, Elisabeth
    Papeix, Caroline
    Mellerio, Charles
    Bertrand, Anne
    Lubetzki, Catherine
    Louapre, Celine
    [J]. JOURNAL OF NEUROLOGY, 2016, 263 (09) : 1869 - 1871
  • [28] Secukinumab: a potential safe option in psoriasis patients affected by multiple sclerosis?
    Megna, Matteo
    Marasca, Claudio
    Ruggiero, Angelo
    Camela, Elisa
    Fabbrocini, Gabriella
    [J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 2020, 59 (08) : E308 - E309
  • [29] Mohan N, 2001, ARTHRITIS RHEUM-US, V44, P2862, DOI 10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO
  • [30] 2-W